Clinical trials: Vehicle, completed
Actinic Keratosis
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of the actinic keratosis
- Trial name
- NCT01962987
- Testing
- Diclofenac sodium
- Where
- 31 sites in United States
- Volunteers
- 476 people
- Sponsor
- Actavis Inc.
Allergic Conjunctivitis
A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
This is a Phase II Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis…
- Trial name
- NCT02082899
- Testing
- Active Comparator EBI-005 5 mg/mL
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Eleven Biotherapeutics
Dermatitis, Atopic
Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by a disturbance of epidermal-barrier function that results in intensely pruritic subacute and chronic eczematous plaques.
- Trial name
- NCT03059693
- Testing
- HAT1 topical cream, Vehicle cream
- Volunteers
- 48 people
- Sponsor
- Haus Bioceuticals
Atopic Dermatitis
A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis
While the repair of the epidermal barrier in atopic dermatitis is of major importance in the treatment of atopic dermatitis, most of the vehicles used may actually cause a worsening of an impaired epidermal barrier.
- Trial name
- NCT01065714
- Testing
- Hydrogel vehicle, Eucerin Lotion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Derm Research, PLLC
Subcutaneous Fat Disorder
Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity
The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity.
- Trial name
- NCT05760248
- Testing
- 10XB-101 Solution for Injection, 6.0%
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- 10xBio, LLC
Dry Eye Disease
Efficacy and Safety of SHR8028 Eye Drops for the Treatment of Dry Eye Disease
The study is being conducted to assess the efficacy, safety and tolerability of SHR8028 eye drops in comparison to the vehicle for the treatment of dry eye disease.
- Trial name
- NCT05841043
- Testing
- SHR8028 eye drops, Vehicle eye drops.
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Plaque Psoriasis
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
This is a parallel group, double blind, vehicle-controlled study in which roflumilast (ARQ-151) cream 0.3%, roflumilast cream 0.15%, or vehicle cream is applied once daily (QD) for 84 days to subjects with chronic plaque…
- Trial name
- ARQ-151-201 (NCT03638258)
- Testing
- Roflumilast Cream 0.3%, Roflumilast Cream 0.15%, Vehicle Cream
- Where
- 30 sites in United States, Canada
- Volunteers
- 331 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Onychomycosis
Efficacy and Safety Study of ME1111 in Patients With Onychomycosis
The purpose of the study is to determine the safety and efficacy of high and low strength of ME1111 solutions compared to the vehicle in the treatment of onychomycosis of the toenail.
- Trial name
- NCT02022215
- Testing
- ME1111 Solution, Low strength, ME1111 Solution, High strength, Matching Vehicle Solution
- Where
- 31 sites in United States
- Volunteers
- 304 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Hypotrichosis
Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence
The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.
- Trial name
- NCT01448525
- Testing
- bimatoprost ophthalmic solution 0.03%, bimatoprost vehicle solution
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Allergan
Onychomycosis of Toenails
Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail
The purpose of this study is to determine whether AN2690 topical solution is a safe and effective treatment for onychomycosis of the toenail.
- Trial name
- NCT01270971
- Testing
- AN2690 Topical Solution, 5%, Solution Vehicle
- Where
- 27 sites in United States
- Volunteers
- 594 people
- Sponsor
- Pfizer
Perennial Allergic Rhinitis
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
The purpose of this study was to assess local nasal adverse effects, as well as systemic effects, of PATANASE nasal spray when compared with Patanase Vehicle, pH 3.7 and Patanase Vehicle, pH 7.0 in patients with perennial…
- Trial name
- NCT00789555
- Testing
- Olopatadine hydrochloride 0.6% nasal spray (PATANASE), Olopatadine nasal spray vehicle, pH 3.7, Olopatadine nasal spray vehicle, pH 7.0
- Where
- United States
- Volunteers
- 1,260 people
- Sponsor
- Alcon Research
Phototoxic Response
Phototoxicity Potential of 6% Bemotrizinol
Phototoxicity Potential of Bemotrizinol (6%)
- Trial name
- NCT05254925
- Testing
- Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Actinic Keratosis
Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients
This is a randomized, vehicle controlled, active comparator, parallel group, study with a total duration of 24 weeks including screening and follow-up.
- Trial name
- NCT02404389
- Testing
- Investigational Treatment, Active comparator
- Where
- 10 sites in Austria, Denmark and 3 more
- Volunteers
- 82 people
- Sponsor
- Novartis Pharmaceuticals
Tinea Pedis
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with…
- Trial name
- NCT01580878
- Testing
- Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle
- Volunteers
- 707 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis Vulgaris
An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A
The purpose of this study is to evaluate the anti-psoriatic effect of injected Botulinum toxin type A compared to that of injected vehicle.
- Trial name
- NCT02577185
- Testing
- Botulinum Toxin Type A, Sodium chloride 9 mg/ml
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- LEO Pharma
Stable Chronic Heart Failure
CD-NP in Subjects With Stable Chronic Heart Failure
This human physiologic study will evaluate the effects of a new drug called CD-NP in individuals with stable chronic heart failure, with a focus on evaluating responses of the kidneys and the hormonal system.
- Trial name
- CD-NP (NCT00620308)
- Testing
- CD-NP
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Tinea Pedis
Clinical Equivalence of Two Butenafine Hydrochloride 1% Creams in Patients With Interdigital Tinea Pedis
To demonstrate comparable safety and efficacy of Taro Pharmaceuticals Inc. butenafine hydrochloride cream 1% (test product) and Lotrimin Ultra® cream (reference listed drug) in the treatment of interdigital tinea pedis, and to…
- Trial name
- NCT00835510
- Testing
- Butenafine cream 1% manufactured by Taro, Lotrimin Ultra (butenafine) 1%, Butenafine Vehicle manufactured by Taro
- Where
- 17 sites in United States, Belize
- Volunteers
- 548 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Atopic Dermatitis
Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis
This is a Phase 1, randomised, double-blind, vehicle controlled study to determine the safety, tolerability, PK and efficacy of twice daily application of topical BioLexa™ lotion, administered for 28 days in adult healthy…
- Trial name
- NCT04544943
- Testing
- BioLexa- Cohort 1, BioLexa- Cohort 2, Gentamicin
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Hoth Therapeutics, Inc.
Acne Vulgaris
A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.
- Trial name
- NCT00664248
- Testing
- IDP-110, Clindamycin, Benzoyl peroxide
- Where
- 35 sites in United States, Belize and 1 more
- Volunteers
- 1,414 people
- Sponsor
- Dow Pharmaceutical Sciences
Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of twice daily ruxolitinib cream in adolescents and adults with Atopic Dermatitis (AD).
- Trial name
- NCT03745638
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 79 sites in United States, Canada and 5 more
- Volunteers
- 631 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.